Rallybio (RLYB) Earnings Analysis

Rallybio (RLYB) next reports earnings on 2026-08-06, consensus EPS -1.28 USD. Last quarter (2026-03-12) it beat with EPS -1.11 USD vs -1.24 USD est (+10.5%). It has beaten estimates in 4/5 recent quarters (80%). Trailing P/E -11.15.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does RLYB next report earnings?

Next earnings date2026-08-06
Consensus EPS estimate-1.28 USD
Revenue estimate0.00B

RLYB earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-12-1.11 USD-1.24 USD+10.5%Beat
2025-11-06-0.14 USD-0.25 USD+44%Beat
2025-08-07-0.22 USD-0.195 USD-12.8%Miss
2025-03-13-0.25 USD-0.27 USD+7.4%Beat
2024-11-07-0.26 USD-0.36 USD+27.8%Beat

Beat rate: 4/5 (80%) over reported quarters with consensus data.

RLYB valuation and analyst view

Trailing P/E-11.15
Trailing EPS-1.37416 USD
Price / book1.88
Dividend yield0.00%
Market cap0.09B
Analyst consensusHold (4 buy / 5 hold / 0 sell)

Related research pages

Frequently asked questions

When is Rallybio (RLYB)'s next earnings date?

Rallybio is next scheduled to report on 2026-08-06, with a consensus EPS estimate of -1.28 USD and revenue estimate of 0.00B.

Did RLYB beat earnings last quarter?

In its 2026-03-12 report, RLYB posted EPS of -1.11 USD versus a -1.24 USD estimate — a beat of 10.5%.

What is RLYB's earnings track record?

Over the last 5 reported quarters with consensus data, RLYB beat estimates 4 times (80%).

What is RLYB's current P/E ratio and EPS?

RLYB trades at a trailing P/E of -11.15 on trailing EPS of -1.3741556774058359 USD.

What do analysts rate RLYB?

Analyst consensus is "Hold" across 9 ratings (0 strong buy, 4 buy, 5 hold, 0 sell, 0 strong sell).